$TXMD
TherapeuticsMD, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021056434 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $25.41M $19.34M $10.70M
YoY Change 31.35% -18.45% 76.03%
Cost Of Revenue $5.282M $3.279M $4.400M
YoY Change 61.09% 127.71% 252.32%
Gross Profit $20.12M $16.06M $6.301M
YoY Change 25.28% -27.89% 30.46%
Gross Profit Margin 79.21% 83.05% 58.88%
Selling, General & Admin $58.44M $39.01M $48.60M
YoY Change 49.81% -13.56% 17.42%
% of Gross Profit 290.4% 242.86% 771.26%
Research & Development $1.605M $2.027M $2.742M
YoY Change -20.82% -50.32% -44.77%
% of Gross Profit 7.98% 12.62% 43.52%
Depreciation & Amortization $200.0K $200.0K $200.0K
YoY Change 0.0% 42.86% 200.5%
% of Gross Profit 0.99% 1.25% 3.17%
Operating Expenses $60.05M $41.04M $51.34M
YoY Change 46.32% -16.84% 10.49%
Operating Profit -$39.92M -$24.97M -$45.04M
YoY Change 59.85% -7.76% 8.17%
Interest Expense $7.518M $7.680M $7.027M
YoY Change -2.11% -237.14% 74.43%
% of Operating Profit
Other Income/Expense, Net $19.00K -$7.638M -$6.938M
YoY Change -100.25% -1191.14% -48.98%
Pretax Income -$47.42M -$32.61M -$51.98M
YoY Change 45.41% 2.01% -5.9%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$47.42M -$32.61M -$51.98M
YoY Change 45.41% 2.02% -5.9%
Net Earnings / Revenue -186.65% -168.61% -485.71%
Basic Earnings Per Share -$5.62
Diluted Earnings Per Share -$5.616M -$119.6K -$191.2K
COMMON SHARES
Basic Shares Outstanding 422.2M 272.6M 271.9M
Diluted Shares Outstanding 8.444M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $104.8M $79.60M $113.8M
YoY Change 31.71% -48.74% -37.75%
Cash & Equivalents $104.8M $79.63M $113.8M
Short-Term Investments
Other Short-Term Assets $10.37M $8.800M $6.700M
YoY Change 17.89% -16.98% -14.1%
Inventory $7.362M $9.900M $10.20M
Prepaid Expenses
Receivables $37.40M $24.10M $18.30M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $160.0M $122.4M $148.9M
YoY Change 30.7% -36.18% -31.21%
LONG-TERM ASSETS
Property, Plant & Equipment $1.388M $11.90M $12.50M
YoY Change -88.34% -7.03% 772.82%
Goodwill
YoY Change
Intangibles $39.62M
YoY Change
Long-Term Investments
YoY Change
Other Assets $253.0K $400.0K $400.0K
YoY Change -36.75% -20.0% -90.0%
Total Long-Term Assets $49.65M $54.90M $56.60M
YoY Change -9.56% -5.67% 97.5%
TOTAL ASSETS
Total Short-Term Assets $160.0M $122.4M $148.9M
Total Long-Term Assets $49.65M $54.90M $56.60M
Total Assets $209.6M $177.3M $205.5M
YoY Change 18.23% -29.08% -16.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $19.59M $16.10M $17.30M
YoY Change 21.69% -33.2% -11.28%
Accrued Expenses $47.05M $20.70M $16.70M
YoY Change 127.29% -38.58% 19.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $15.00M
YoY Change
Total Short-Term Liabilities $86.27M $47.30M $46.50M
YoY Change 82.38% -29.72% 11.04%
LONG-TERM LIABILITIES
Long-Term Debt $171.7M $237.1M $243.8M
YoY Change -27.57% 21.97% 25.61%
Other Long-Term Liabilities $8.984M $8.900M $9.300M
YoY Change 0.94% -6.32% 272.0%
Total Long-Term Liabilities $171.7M $246.0M $253.1M
YoY Change -30.19% 20.65% 30.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $86.27M $47.30M $46.50M
Total Long-Term Liabilities $171.7M $246.0M $253.1M
Total Liabilities $267.0M $293.3M $299.6M
YoY Change -8.97% 8.15% 25.64%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$57.36M -$116.0M -$94.09M
YoY Change
Total Liabilities & Shareholders Equity $209.6M $177.3M $205.5M
YoY Change 18.23% -29.08% -16.65%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$47.42M -$32.61M -$51.98M
YoY Change 45.41% 2.02% -5.9%
Depreciation, Depletion And Amortization $200.0K $200.0K $200.0K
YoY Change 0.0% 42.86% 200.5%
Cash From Operating Activities -$38.22M -$34.05M -$55.99M
YoY Change 12.26% 29.86% 10.83%
INVESTING ACTIVITIES
Capital Expenditures -$182.0K -$260.0K -$400.0K
YoY Change -30.0% -80.0% -66.39%
Acquisitions
YoY Change
Other Investing Activities $0.00 $40.00K
YoY Change -300.0%
Cash From Investing Activities -$182.0K -$260.0K -$370.0K
YoY Change -30.0% -80.0% -69.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 31.82M 100.0K 100.0K
YoY Change 31722.0% 900.0% -99.91%
NET CHANGE
Cash From Operating Activities -38.22M -34.05M -55.99M
Cash From Investing Activities -182.0K -260.0K -370.0K
Cash From Financing Activities 31.82M 100.0K 100.0K
Net Change In Cash -6.583M -34.21M -56.26M
YoY Change -80.76% 24.35% -193.83%
FREE CASH FLOW
Cash From Operating Activities -$38.22M -$34.05M -$55.99M
Capital Expenditures -$182.0K -$260.0K -$400.0K
Free Cash Flow -$38.04M -$33.79M -$55.59M
YoY Change 12.58% 35.59% 12.69%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M12D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y10M24D
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
86193000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16637000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66691000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2027000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5666000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
41037000
us-gaap Net Income Loss
NetIncomeLoss
-141437000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
163000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3279000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14101000
CY2020Q3 us-gaap Gross Profit
GrossProfit
16063000
us-gaap Gross Profit
GrossProfit
54172000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22373000
us-gaap Operating Expenses
OperatingExpenses
158550000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24974000
us-gaap Operating Income Loss
OperatingIncomeLoss
-104378000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68273000
CY2020Q3 us-gaap Interest Expense
InterestExpense
7680000
us-gaap Interest Expense
InterestExpense
25341000
us-gaap Interest Expense
InterestExpense
20969000
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
42000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
264000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
466000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7638000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25077000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-20503000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32612000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-129455000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-141437000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-32612000
us-gaap Net Income Loss
NetIncomeLoss
-129455000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
272565000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
388111000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
271969000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-124001000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
150899000
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
50000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2957000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-9478000
CY2021Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
228000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
134000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2510000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-42652000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-49074000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
31819000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7312000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47420000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-57360000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
72000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2366000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-56849000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-45210000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3003000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-51976000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-94088000
CY2020Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
106000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7428000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3133000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-32612000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-116033000
us-gaap Net Income Loss
NetIncomeLoss
-129455000
us-gaap Net Income Loss
NetIncomeLoss
-141437000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3091000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3039000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
540000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-47000
txmd Inventory Charge
InventoryCharge
1082000
txmd Inventory Charge
InventoryCharge
5744000
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
4158000
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
1645000
us-gaap Share Based Compensation
ShareBasedCompensation
12779000
us-gaap Share Based Compensation
ShareBasedCompensation
8502000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
726000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
1719000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5560000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-384000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
451000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3816000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2831000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2038000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1476000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3072000
txmd Increasedecrease In Accrued Expenses And Other Current Liabilities
IncreasedecreaseInAccruedExpensesAndOtherCurrentLiabilities
13504000
txmd Increasedecrease In Accrued Expenses And Other Current Liabilities
IncreasedecreaseInAccruedExpensesAndOtherCurrentLiabilities
-3813000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
758000
txmd Adjustments To Reconcile Net Profit Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetProfitLossToCashProvidedByUsedInOperatingActivities
-26320000
txmd Adjustments To Reconcile Net Profit Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetProfitLossToCashProvidedByUsedInOperatingActivities
-12323000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103135000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129114000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
675000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1065000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-709000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1104000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
182881000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
302000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
272000
txmd Proceeds From Sale Of Common Stock Related To Employee Stock Purchase Plan
ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan
134000
us-gaap Repayments Of Debt
RepaymentsOfDebt
50000000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
50000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5118000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1250000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
128199000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49022000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
24355000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-81196000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80486000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160830000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104841000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79634000
txmd Warrants Issued In Relation To Debt Financing Agreement
WarrantsIssuedInRelationToDebtFinancingAgreement
7428000
us-gaap Interest Paid Net
InterestPaidNet
19675000
us-gaap Interest Paid Net
InterestPaidNet
12032000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts, including type of operating expenses, reported in prior periods in the financial statements have been reclassified to conform to the current period’s presentation.</p>
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1118000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
540000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
307000
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1351000
CY2021Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3487000
CY2020Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
4423000
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
688000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
220000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3187000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3350000
CY2021Q3 us-gaap Inventory Net
InventoryNet
7362000
CY2020Q4 us-gaap Inventory Net
InventoryNet
7993000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2329000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1741000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1388000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1942000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
3801000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2568000
CY2021Q3 txmd Paragraph Four Legal Proceeding Costs
ParagraphFourLegalProceedingCosts
2858000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3715000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4975000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10374000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7543000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3717000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3683000
CY2021Q3 us-gaap Depreciation
Depreciation
200000
CY2020Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
600000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
46328000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7055000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
39273000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
45674000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4552000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
41122000
CY2021Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
46672000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7055000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
39617000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
45997000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4552000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41445000
CY2021Q3 txmd Number Of Issued Patents
NumberOfIssuedPatents
87
CY2020Q4 txmd Number Of Issued Patents
NumberOfIssuedPatents
77
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
584509
CY2020Q4 txmd Accrued Rebates Current
AccruedRebatesCurrent
11011000
CY2021Q3 txmd Accrued Sales Returns Reserve And Coupons Current
AccruedSalesReturnsReserveAndCouponsCurrent
3200000
CY2020Q4 txmd Accrued Sales Returns Reserve And Coupons Current
AccruedSalesReturnsReserveAndCouponsCurrent
7057000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.06
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
117000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
60000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.21
CY2021Q3 txmd Accrued Payroll And Related Costs
AccruedPayrollAndRelatedCosts
14346000
CY2020Q4 txmd Accrued Payroll And Related Costs
AccruedPayrollAndRelatedCosts
11179000
CY2021Q3 txmd Accrued Rebates Current
AccruedRebatesCurrent
15421000
CY2021Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
6223000
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
228000
CY2021Q3 txmd Accrued Wholesale Distributor Fees
AccruedWholesaleDistributorFees
4626000
CY2020Q4 txmd Accrued Wholesale Distributor Fees
AccruedWholesaleDistributorFees
2632000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2477000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
925000
CY2021Q3 txmd Other Accrued Expenses And Current Liabilities
OtherAccruedExpensesAndCurrentLiabilities
5381000
CY2020Q4 txmd Other Accrued Expenses And Current Liabilities
OtherAccruedExpensesAndCurrentLiabilities
5138000
CY2021Q3 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
51674000
CY2020Q4 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
38170000
CY2021Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
13262000
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
12302000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
186738000
CY2021Q3 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
1477000
CY2020Q3 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
953000
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
4158000
us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
1645000
CY2021Q3 us-gaap Interest Expense
InterestExpense
7518000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
61000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4885000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
483000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.59
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
237698000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
15000000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
171738000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
237698000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
5000000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
5000000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
5000000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
10000000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
41250000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
41250000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
41250000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
5391000
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
6727000
us-gaap Interest Expense Debt
InterestExpenseDebt
17175000
us-gaap Interest Expense Debt
InterestExpenseDebt
19324000
CY2021Q3 txmd Debt Interest Prepayment Fee
DebtInterestPrepaymentFee
650000
txmd Debt Interest Prepayment Fee
DebtInterestPrepaymentFee
4008000
CY2020Q3 us-gaap Interest Expense
InterestExpense
7680000
us-gaap Interest Expense
InterestExpense
25341000
us-gaap Interest Expense
InterestExpense
20969000
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
5000000.0
CY2021Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
13262000
CY2021Q3 txmd Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price Eligible Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceEligibleOptions
5.01
CY2021Q3 txmd Number Of Eligible Employees Elected To Exchange Eligible Options
NumberOfEligibleEmployeesElectedToExchangeEligibleOptions
69
CY2021Q3 txmd Share Based Compensation Arrangement By Share Based Payment Options Granted To Purchase Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentOptionsGrantedToPurchaseCommonStock
4493000
CY2021Q3 txmd Percentage Of Shares Of Common Stock Underlying Eligible Options
PercentageOfSharesOfCommonStockUnderlyingEligibleOptions
0.915
CY2021Q3 txmd Number Of Annual Installments Vest
NumberOfAnnualInstallmentsVest
3
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.80
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
152000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
19863000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18413000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.40
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
17228000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.53
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7300000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12800000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8500000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
22700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2021Q3 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Remainder Of Fiscal Year
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedRemainderOfFiscalYear
3280000
CY2021Q3 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year One
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearOne
10693000
CY2021Q3 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year Two
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearTwo
6206000
CY2021Q3 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year Three
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearThree
2465000
CY2021Q3 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year Four
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearFour
6000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
22650000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
25406000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19342000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
68273000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
42294000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47420000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-32612000
us-gaap Net Income Loss
NetIncomeLoss
-129455000
us-gaap Net Income Loss
NetIncomeLoss
-141437000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
422216000
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
272565000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
388111000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
271969000
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
422216000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
272565000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
388111000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
271969000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
49327000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34826000

Files In Submission

Name View Source Status
0001564590-21-056434-index-headers.html Edgar Link pending
0001564590-21-056434-index.html Edgar Link pending
0001564590-21-056434.txt Edgar Link pending
0001564590-21-056434-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gprpiqfusrm4000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
txmd-10q_20210930.htm Edgar Link pending
txmd-10q_20210930_htm.xml Edgar Link completed
txmd-20210930.xsd Edgar Link pending
txmd-20210930_cal.xml Edgar Link unprocessable
txmd-20210930_def.xml Edgar Link unprocessable
txmd-20210930_lab.xml Edgar Link unprocessable
txmd-20210930_pre.xml Edgar Link unprocessable
txmd-ex105_310.htm Edgar Link pending
txmd-ex311_6.htm Edgar Link pending
txmd-ex312_8.htm Edgar Link pending
txmd-ex321_9.htm Edgar Link pending
txmd-ex322_7.htm Edgar Link pending